M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells.

PubWeight™: 2.02‹?› | Rank: Top 2%

🔗 View Article (PMID 21709158)

Published in J Immunol on June 27, 2011


Moniek Heusinkveld1, Peggy J de Vos van Steenwijk, Renske Goedemans, Tamara H Ramwadhdoebe, Arko Gorter, Marij J P Welters, Thorbald van Hall, Sjoerd H van der Burg

Author Affiliations

1: Department of Clinical Oncology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands.

Articles citing this

Regulation of immune responses by prostaglandin E2. J Immunol (2012) 3.93

Differential macrophage programming in the tumor microenvironment. Trends Immunol (2012) 3.18

Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 2.39

Live imaging of tumor initiation in zebrafish larvae reveals a trophic role for leukocyte-derived PGE₂. Curr Biol (2012) 1.80

Macrophage phenotypes during tissue repair. J Leukoc Biol (2013) 1.67

In vitro generation of monocyte-derived macrophages under serum-free conditions improves their tumor promoting functions. PLoS One (2012) 1.57

Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech (2013) 1.55

Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res (2012) 1.37

PGE(2) induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. J Immunol (2012) 1.35

Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31

The role of macrophage polarization in infectious and inflammatory diseases. Mol Cells (2014) 1.28

Lipid metabolic reprogramming in cancer cells. Oncogenesis (2016) 1.16

Therapy of human papillomavirus-related disease. Vaccine (2012) 1.11

The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol (2013) 1.06

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med (2013) 1.02

Lipopolysaccharide-induced M2 to M1 macrophage transformation for IL-12p70 production is blocked by Candida albicans mediated up-regulation of EBI3 expression. PLoS One (2013) 1.00

Monocyte and Macrophage Plasticity in Tissue Repair and Regeneration. Am J Pathol (2015) 0.99

Manifestations of immune tolerance in the human female reproductive tract. Front Immunol (2013) 0.94

Lipopolysaccharide-activated dendritic cells: "exhausted" or alert and waiting? J Immunol (2012) 0.93

Generation of myeloid-derived suppressor cells using prostaglandin E2. Transplant Res (2012) 0.93

Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. Front Immunol (2014) 0.92

Functional characterization of a STAT3-dependent dendritic cell-derived CD14(+) cell population arising upon IL-10-driven maturation. Oncoimmunology (2013) 0.92

The adipocyte-inducible secreted phospholipases PLA2G5 and PLA2G2E play distinct roles in obesity. Cell Metab (2014) 0.91

RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1α release, and efficient paracrine dendritic cell activation. Oncotarget (2015) 0.91

Inhibition of CSF-1R supports T-cell mediated melanoma therapy. PLoS One (2014) 0.91

A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins. Clin Cancer Res (2012) 0.91

Serum-starved adipose-derived stromal cells ameliorate crescentic GN by promoting immunoregulatory macrophages. J Am Soc Nephrol (2013) 0.89

Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14(+) PD-L1(+) phenotype in prostate cancer. Oncoimmunology (2014) 0.89

HPV associated tumor cells control tumor microenvironment and leukocytosis in experimental models. Immun Inflamm Dis (2014) 0.88

Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal (2012) 0.88

Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area. Oncotarget (2015) 0.87

Dendritic Cell Plasticity in Tumor-Conditioned Skin: CD14(+) Cells at the Cross-Roads of Immune Activation and Suppression. Front Immunol (2013) 0.87

Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol (2016) 0.86

Gastrointestinal microbes interact with canine adipose-derived mesenchymal stem cells in vitro and enhance immunomodulatory functions. Stem Cells Dev (2014) 0.86

Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity. Cell Death Dis (2013) 0.86

High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time. PLoS One (2013) 0.86

Correlations between immune response and vascularization qRT-PCR gene expression clusters in squamous cervical cancer. Mol Cancer (2015) 0.83

Immunotherapy of human papilloma virus induced disease. Open Virol J (2012) 0.83

Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies. Mediators Inflamm (2016) 0.83

Dectin-1 Activation by a Natural Product β-Glucan Converts Immunosuppressive Macrophages into an M1-like Phenotype. J Immunol (2015) 0.82

Establishment of the cell line, HeLa-CD14, transfected with the human CD14 gene. Oncol Lett (2012) 0.82

Liver myofibroblasts up-regulate monocyte CD163 expression via PGE2 during hepatitis B induced liver failure. J Transl Med (2014) 0.82

Secreted Factors from Colorectal and Prostate Cancer Cells Skew the Immune Response in Opposite Directions. Sci Rep (2015) 0.82

Grapefruit-derived nanovectors deliver miR-18a for treatment of liver metastasis of colon cancer by induction of M1 macrophages. Oncotarget (2016) 0.82

CD14(+) macrophage-like cells as the linchpin of cervical cancer perpetrated immune suppression and early metastatic spread: A new therapeutic lead? Oncoimmunology (2015) 0.81

The robust and modulated biomarker network elicited by the Plasmodium vivax infection is mainly mediated by the IL-6/IL-10 axis and is associated with the parasite load. J Immunol Res (2014) 0.81

Cervical cancer cell supernatants induce a phenotypic switch from U937-derived macrophage-activated M1 state into M2-like suppressor phenotype with change in Toll-like receptor profile. Biomed Res Int (2014) 0.81

Cyclooxygenase-2 in tumor-associated macrophages promotes breast cancer cell survival by triggering a positive-feedback loop between macrophages and cancer cells. Oncotarget (2015) 0.81

15-Lipoxygenase metabolites of α-linolenic acid, [13-(S)-HPOTrE and 13-(S)-HOTrE], mediate anti-inflammatory effects by inactivating NLRP3 inflammasome. Sci Rep (2016) 0.80

The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation. Nat Commun (2015) 0.80

Anti-inflammatory properties of prostaglandin E2: deletion of microsomal prostaglandin E synthase-1 exacerbates non-immune inflammatory arthritis in mice. Prostaglandins Leukot Essent Fatty Acids (2013) 0.80

Critical role of TLR2 and MyD88 for functional response of macrophages to a group IIA-secreted phospholipase A2 from snake venom. PLoS One (2014) 0.79

Anti-LFA-1 antibodies enhance metastasis of ocular lymphoma to the brain and contralateral eye. Clin Exp Metastasis (2012) 0.78

The risk of heart failure and cardiometabolic complications in obesity may be masked by an apparent healthy status of normal blood glucose. Oxid Med Cell Longev (2013) 0.78

Moderate-intensity exercise alters markers of alternative activation in circulating monocytes in females: a putative role for PPARγ. Eur J Appl Physiol (2016) 0.78

CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function. Oncotarget (2017) 0.77

Ly6C- Monocytes Regulate Parasite-Induced Liver Inflammation by Inducing the Differentiation of Pathogenic Ly6C+ Monocytes into Macrophages. PLoS Pathog (2015) 0.77

Bidirectional crosstalk via IL-6, PGE2 and PGD2 between murine myofibroblasts and alternatively activated macrophages enhances anti-inflammatory phenotype in both cells. Br J Pharmacol (2016) 0.77

Tumour cell derived effects on monocyte/macrophage polarization and function and modulatory potential of Viscum album lipophilic extract in vitro. BMC Complement Altern Med (2015) 0.77

Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists. Oncoimmunology (2014) 0.77

A subset of CD163(+) macrophages displays mixed polarizations in discoid lupus skin. Arthritis Res Ther (2015) 0.76

A novel approach to the discovery of anti-tumor pharmaceuticals: searching for activators of liponecrosis. Oncotarget (2016) 0.76

Tumour-processed osteopontin and lactadherin drive the protumorigenic reprogramming of microglia and glioma progression. Oncogene (2016) 0.76

Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells. Oncoimmunology (2015) 0.76

Activation of E-prostanoid 3 receptor in macrophages facilitates cardiac healing after myocardial infarction. Nat Commun (2017) 0.75

Implications of chemokine receptors and inflammatory lipids in cancer. Immunotargets Ther (2013) 0.75

Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma. PLoS One (2017) 0.75

All Trans Retinoic Acid, Transforming Growth Factor β and Prostaglandin E2 in Mouse Plasma Synergize with Basophil-Secreted Interleukin-4 to M2 Polarize Murine Macrophages. PLoS One (2016) 0.75

High Concentrations of TNF-α Induce Cell Death during Interactions between Human Umbilical Cord Mesenchymal Stem Cells and Peripheral Blood Mononuclear Cells. PLoS One (2015) 0.75

Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages. Oncotarget (2016) 0.75

Are macrophages in tumors good targets for novel therapeutic approaches? Mol Cells (2014) 0.75

Monitoring of the Immune Dysfunction in Cancer Patients. Vaccines (Basel) (2016) 0.75

Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents. Cancer Immunol Immunother (2015) 0.75

Impaired lymphatic function accelerates cancer growth. Oncotarget (2016) 0.75

Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer. Cancer Immunol Immunother (2016) 0.75

Niemann-pick type C2 deficiency in human fibroblasts confers robust and selective activation of prostaglandin E2 biosynthesis. J Biol Chem (2013) 0.75

Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway. Int J Biol Sci (2016) 0.75

Immunopathogenesis of HPV-Associated Cancers and Prospects for Immunotherapy. Viruses (2017) 0.75

Systemic and intestinal levels of factor XIII-A: the impact of inflammation on expression in macrophage subtypes. J Gastroenterol (2015) 0.75

A Role for CD154, the CD40 Ligand, in Granulomatous Inflammation. Mediators Inflamm (2017) 0.75

PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol (2017) 0.75

Adipocytes and Macrophages Interplay in the Orchestration of Tumor Microenvironment: New Implications in Cancer Progression. Front Immunol (2017) 0.75

Articles by these authors

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79

A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature (2013) 3.46

Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 2.39

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31

Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06

Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res (2009) 2.04

High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res (2007) 1.96

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93

Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res (2004) 1.90

Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A (2010) 1.67

Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66

Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res (2010) 1.59

Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res (2008) 1.54

CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol (2007) 1.54

Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A (2007) 1.53

Complement function in mAb-mediated cancer immunotherapy. Trends Immunol (2004) 1.52

DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res (2007) 1.45

Prevention of adhesion to prosthetic mesh: comparison of different barriers using an incisional hernia model. Ann Surg (2003) 1.44

Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res (2003) 1.40

Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res (2005) 1.38

Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples. PLoS Comput Biol (2013) 1.35

Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res (2005) 1.30

Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res (2013) 1.28

Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med (2007) 1.28

Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res (2009) 1.27

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer (2009) 1.26

Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One (2011) 1.26

Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res (2009) 1.26

A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. Int J Cancer (2010) 1.25

Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res (2011) 1.24

Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer. BMC Genomics (2007) 1.24

Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol (2010) 1.24

Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci U S A (2009) 1.24

Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem (2007) 1.23

Therapeutic cancer vaccines. J Clin Invest (2015) 1.23

Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res (2002) 1.22

HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes. Proc Natl Acad Sci U S A (2011) 1.17

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol (2008) 1.16

Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLoS Pathog (2013) 1.15

In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J Immunol (2010) 1.15

Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines (2007) 1.14

Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature (2016) 1.12

Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res (2003) 1.12

Vaccination for treatment and prevention of cancer in animal models. Adv Immunol (2006) 1.11

Therapy of human papillomavirus-related disease. Vaccine (2012) 1.11

Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res (2008) 1.11

Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer (2008) 1.11

Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosomes Cancer (2007) 1.11

Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Hum Immunol (2003) 1.07

Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res (2006) 1.06

Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding. Expert Rev Vaccines (2008) 1.06

Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer (2010) 1.06

Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int J Cancer (2006) 1.05

The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects. J Exp Med (2009) 1.05

Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother (2012) 1.05

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med (2013) 1.02

Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma. Pigment Cell Melanoma Res (2013) 1.02

Strategies to counteract MHC-I defects in tumors. Curr Opin Immunol (2011) 1.02

Tumor-specific regulatory T cells in cancer patients. Hum Immunol (2008) 1.01

An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res (2010) 1.00

Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen. Cancer Res (2008) 0.99

Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother (2015) 0.99

Transforming growth factor-beta1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. Hum Pathol (2002) 0.99

The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int J Cancer (2010) 0.98

Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunol Immunother (2012) 0.98

Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther (2014) 0.97

Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival. Mod Pathol (2008) 0.97

A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother (2012) 0.97

Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Semin Immunol (2013) 0.96

Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv Drug Deliv Rev (2006) 0.96

Identification, isolation, and culture of HLA-A2-specific B lymphocytes using MHC class I tetramers. J Immunol (2003) 0.95